Skip to main content
Journal cover image

Phase II study of gemcitabine in advanced colorectal adenocarcinoma.

Publication ,  Journal Article
Moore, DF; Pazdur, R; Daugherty, K; Tarassoff, P; Abbruzzese, JL
Published in: Invest New Drugs
November 1992

A phase II trial of gemcitabine (difluorodeoxycytidine) was conducted in 14 patients with advanced colorectal adenocarcinoma. Gemcitabine was administered intravenously over 30 minutes at weekly intervals for 3 consecutive weeks each month. The starting dose was 800 mg/m2, with dose escalation as tolerated. No complete or partial response were observed. Ten patients experienced progressive disease while on therapy. Toxic effects were primarily hematologic in nature. Grade 3 toxicities included leukopenia (one patient at 1000 mg/m2), granulocytopenia (two patients at 800 mg/m2), anemia (two patients at 800 mg/m2), and myalgia (one patient at 800 mg/m2). No grade 4 toxic effects or treatment-associated deaths were observed. Gemcitabine, at the doses and schedule used in this study, did not demonstrate activity against advanced colorectal adenocarcinoma.

Duke Scholars

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

November 1992

Volume

10

Issue

4

Start / End Page

323 / 325

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Gemcitabine
  • Female
  • Drug Administration Schedule
  • Deoxycytidine
  • Colorectal Neoplasms
  • Antimetabolites, Antineoplastic
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moore, D. F., Pazdur, R., Daugherty, K., Tarassoff, P., & Abbruzzese, J. L. (1992). Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs, 10(4), 323–325. https://doi.org/10.1007/BF00944189
Moore, D. F., R. Pazdur, K. Daugherty, P. Tarassoff, and J. L. Abbruzzese. “Phase II study of gemcitabine in advanced colorectal adenocarcinoma.Invest New Drugs 10, no. 4 (November 1992): 323–25. https://doi.org/10.1007/BF00944189.
Moore DF, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs. 1992 Nov;10(4):323–5.
Moore, D. F., et al. “Phase II study of gemcitabine in advanced colorectal adenocarcinoma.Invest New Drugs, vol. 10, no. 4, Nov. 1992, pp. 323–25. Pubmed, doi:10.1007/BF00944189.
Moore DF, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL. Phase II study of gemcitabine in advanced colorectal adenocarcinoma. Invest New Drugs. 1992 Nov;10(4):323–325.
Journal cover image

Published In

Invest New Drugs

DOI

ISSN

0167-6997

Publication Date

November 1992

Volume

10

Issue

4

Start / End Page

323 / 325

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Humans
  • Gemcitabine
  • Female
  • Drug Administration Schedule
  • Deoxycytidine
  • Colorectal Neoplasms
  • Antimetabolites, Antineoplastic